Apogee Therapeutics CMO Dambkowski Carl Sells 2,725 Shares at $37.78 Per Share

Apogee Therapeutics, Inc. (APGE) has disclosed that Chief Medical Officer Dambkowski Carl has executed a transaction involving the sale of 2,725 shares of the company's common stock at a price per share of $37.78 on August 6, 2023.

In a recent development, Apogee Therapeutics, Inc. (NASDAQ: APGE) has disclosed that Chief Medical Officer Carl Dambkowski executed a transaction involving the sale of 2,725 shares of the company's common stock. The sale occurred on August 6, 2023, at a price per share of $37.78. This transaction follows a previous sale by Dambkowski in July 2023, where he sold 10,090 shares at an average price of $45.09 [1].

The insider's latest sale is significant, as it represents a notable decrease in his ownership stake. Prior to the sale, Dambkowski owned 238,998 shares, valued at $10,776,419.82. After the transaction, his ownership decreased to 236,273 shares, valued at $8,921,074.60. This sale constitutes a 4.05% decrease in his ownership, reflecting a strategic decision to reduce his holding in the company [1].

The insider's trading activity is subject to scrutiny, particularly given the recent increase in short interest in Apogee Therapeutics. As of the latest available data, 24.62% of the float has been sold short, indicating a significant level of bearish sentiment among investors [2]. This heightened short interest, coupled with the insider's sale, could influence investor perceptions of the company's prospects.

Apogee Therapeutics continues to operate in the biotechnology sector, focusing on the development of biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company's primary products include APG777 and APG808, extended half-life monoclonal antibodies for AD and COPD, respectively [2].

Despite the recent insider sale and increased short interest, Apogee Therapeutics has maintained a "Buy" consensus rating from analysts. The average price target set by analysts for the next year is $99.00, with Wedbush and Guggenheim providing target prices of $90.00 and $116.00, respectively [1].

Investors should closely monitor Apogee Therapeutics' financial performance and any future insider trading activities to gauge the company's prospects and potential risks.

References:
[1] https://www.marketbeat.com/instant-alerts/apogee-therapeutics-inc-nasdaqapge-receives-average-rating-of-buy-from-analysts-2025-08-05/
[2] https://www.marketbeat.com/stocks/NASDAQ/APGE/